Orexo AB (FRA:C5G)
€ 0.86 -0.025 (-2.82%) Market Cap: 30.87 Mil Enterprise Value: 72.14 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 51/100

Q2 2020 Orexo AB Earnings Call Transcript

Jul 16, 2020 / 01:00PM GMT
Release Date Price: €6.29 (-1.56%)
Operator

Hello and welcome to the Orexo Interim Reports Q2 2020. (Operator Instructions) Today, I'm pleased to present Nikolaj Sørensen, CEO; and Joseph DeFeo, CFO. Please begin your meeting.

Nikolaj SÃ;rensen;publ;President;CEO
Orexo AB

¸ - ()-&

Thank you very much and welcome to the second interim report. I will also say we have received some questions through e-mails and Lena Wange, who is our Investor Relations Director, who will join the call in the end for the Q&A session and ask these questions if they have not already been asked or addressed during the presentation.

So this quarter has, in many ways been a very exciting quarter for Orexo. We have invested into a completely new area in digital therapies where we, due to the circumstances with the COVID-19 pandemic, have had an opportunity and also both commercially and regulatory, to accelerate the launch of vorvida and for deprexis. We have also, during the quarter, seen that our R&D pipeline has progressed according to plan. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot